On May 29, 2020, the Food and Drug Administration (FDA) approved the combination of Cyramza (ramucirumab) and Tarceva (erlotinib) for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having changes in EGFR called exon 19 deletions or exon 21 L858R mutations. The FDA based their approval on the results of the clinical trial RELAY which showed that patients receiving Cyramza and Tarceva went longer periods of time without progression and their response to treatment lasted longer than those receiving Tarceva by itself.
The combination Cyramza and Tarceva and being available as a first line targeted therapy option gives patients whose tumors have changes in EGFR a new choice for treatment.
Leave A Comment